Company Overview: Vericel is a biopharmaceutical company specializing in cellular treatments for severe burn care and sports medicine. The company's flagship product, MACI, is used for knee cartilage replacement and has been a significant growth driver, achieving a 22% revenue increase along with record numbers of implants, biopsies, and surgeon usage. Product...
Looking at the micro data, we have an uptrend where we're following along the rising bottom. Looking a bit further out, we can see we're in a bullish wedge. General trends say that this will come up, and the company will have only good news about their trials progressing which will drive the price higher. Very near to $2 by the end of February, and we could...
After the good news this morning, the CNTB just got a big dip from one of the whales with weak resistance buyback force resulting in a sum of 3mil shares exchanged between buy and sale leading to a current ~$1.4. However, I noticed a similar pattern around October time where a bullish push for $1.2 and a big dip after that down to $0.79. This dip is almost 36% dip...
Here is a quick analysis of the CNTB chart and how it runs for whoever is interested in startup stocks. The advisory board of CNTB seems to be solid with Eli Lilly holding roughly 3.5% shares. This is not financial advice, please invest with care!
Without looking at the news, the CNTB should have gone down to get more air and stay around the $1.6 zone to be attractive. However, the new news regarding Simcere obtained the exclusive deal with CNTB regarding phase 3 drug rademikibart providing CNTB immediate big funding ($21M-$121M). This may signal a very bullish run if the market receives this news as...
FSD Pharma and it's subsidiaries have progress in advancing their three drug candidates (PEA, Lycid Psych. & Lucid-MS) through clinical phases. After partnering with covar pharmaceuticals and Acquiring Lucid Psycheceuticals (subsidiary of FSD pharma Inc.), HUGE was able to recently purchase a new facility in Cobourg Ontario (CAD $17 million) which will be closing...
crab harmonic pattern: X=$31 AB=0.38 XA BC=0.88 AB tp1=1.6 BC=$4.8 tp2=2.6 BC=$19 tp3=3.6 BC=$78 tp4=1.6 XA=$410
we have a shark pattern on the 2nd wave with a reversal point of $2.23 and on $2.1 C-1-2 could form the cypher pattern. so we have a reversal PRZ with two patterns and since the target of both two patterns is between $11 and $11.7 also we have a target PRZ. the candle of this week could be a beautiful reversal green hammer.
shark harmonic pattern targets: AB=0.61 XA BC=1.6 AB tp1=0.88 XA=$25 tp2=1.13 XA=$38 tp3=1.6 BC=$82 tp4=2.24 BC=$340 other targets: tp5=0.78 BC=$12 tp6=0.88 BC=$15 tp7=0.78 XA=$$21 tp8=1.6 XA=1.6 BC=$82
*Wait till the pattern completed and the candle confirmation* if ABC cypher: BC=1.13 AB=$2.16 or BC=1.42 AB=$1.4 if ABC shark: BC=1.13 AB=$2.16 or BC=1.6 AB=$1.02 I used the cypher pattern with BC=1.42 AB scenario and bat pattern with 4-5=0.88 3-4
I trapped in the 2st wave but you have the 3rd wave!
Wave 1 is the start of a bullish trend, it is SUPER hard to catch, usually everyone is pessimistic on the stock and nobody believes the move that its making. Wave 2. where we currently are and possibly just finished.... usually has lower volume than wave 1, The price usually does NOT go below 0.618 fib retracement line (which we haven't) :), however sometimes but...
* This is not financial advice. This is my non-expert opinion. * Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to...
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy...
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments Under the terms of the exclusive licensing agreement, La...
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes. Key findings include: - Marrow blast reductions observed in all evaluable patients (6 patients). - 6 of 7 patients enrolled remain on study. - Patients enrolled experienced a...
Big Rock Partners Acquisition Corp. Announces Merger with NeuroRx, Inc. Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics...
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. - Strategic investment from single biotech-focused institutional investor - - Enables...